Why autologous product unit economics go wrong
In traditional pharmaceutical manufacturing a batch makes thousands of identical doses and cost per unit is a simple allocation of batch cost across units produced. Autologous cell therapy reverses that. One manufacturing run creates one dose for one named patient, and that dose has a chain of custody from the collection center to bedside infusion, often passing through multiple facilities, couriers and temperature states.
Standard NetSuite configurations built for batch manufacturing and standard ERP costing models do not natively account for this pattern. Organizations that implement without addressing it are left tracking the true cost of therapy delivery on a parallel spreadsheet, disconnected from the financial system of record.
Follow the vein-to-vein chain of custody to financial events
To build a complete vein-to-vein cost model, the ERP must acknowledge each step in the chain as an independent cost and inventory event: apheresis collection at the clinical site, cryopreservation and shipment to the manufacturing facility, in-process manufacturing and quality testing, cryopreservation of the final product, return shipment to the treatment site, and final infusion.
Each stage has an owner, a cost, and often a different vendor or internal cost center. NetSuite can track this as a work-in-process item moving through a defined set of locations and statuses, but the location and status structure must be designed to reflect the actual chain of custody and not a generic manufacturing routing.
Cost driver of manufacturing suite scheduling
Cell therapy manufacturing suites are a scarce and expensive resource, and suite utilization is one of the biggest cost drivers in the entire vein-to-vein chain. A suite that sits idle between batches of patients has fixed cost and no production to absorb that cost. A fully loaded suite can efficiently absorb overhead, but introduces scheduling risk if a batch requires rework or increased processing time.
Manufacturing and finance operations need integrated visibility of suite scheduling and utilization, preferably on the same system that captures cost of goods. Organizations using a separate planning tool for suite scheduling that is disconnected from NetSuite lose the visibility to cost variance driven by utilization until well after the period is closed.
Accounting for batch failure and out-of-specification product
Batch failures in autologous manufacturing are not a risk to model that is hypothetical. They are an event that happens again and again, for which finance needs a defined accounting treatment. If a batch does not meet release specifications, you need to know how much it cost you up to that point and whether you should expense it immediately, capitalize it while you try to manufacture it again, or spread it over successful batches as a normal yield loss.
The decision is a real income statement impact at typical autologous failure rates and needs to be a documented accounting policy applied consistently in the ERP, not a judgment call made differently each quarter by whoever is closing the books that month.
Allocation of logistics and courier expenses
The cell and gene therapy companies are incurring significant and increasing costs in specialized cryogenic courier services, chain-of-identity tracking systems, and temperature-monitoring logistics providers. To get an accurate cost-per-dose figure, these costs need to be captured at the dose level, and not pooled as a general logistics expense, if the organization wants accurate numbers.
NetSuite’s item receipt and shipment workflows are configured in such a way that the logistics cost is captured against the actual patient dose record, not a general ledger logistics expense account, enabling dose-level costing.
Creating a real cost-per-dose model
A defensible cost-per-dose model aggregates collection cost, shipment and cryopreservation cost, manufacturing suite time allocated by actual usage, quality testing cost, a documented treatment of failed batch cost, and return logistics cost. By capturing each of these in NetSuite against the patient dose record instead of reconstructing them after the fact, the finance team can deliver accurate margin analysis by program and support pricing and reimbursement conversations with real data.
This is also the model investors, partners and regulators are increasingly expecting to see as autologous therapies move toward broader commercial reimbursement discussions. A cost model built in spreadsheets doesn’t stand up the same way a cost model embedded in the system of record does.